Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Inclusion Criteria:~* Patients who are diagnosed with Crohn's disease (according to the Crohn's disease diagnostic criteria developed by the research group on intractable inflammatory bowel disorders \[Shimoyama group, January 25, 2002\]) at least 24 weeks before the starting date of the observation period~* Patients with Crohn's Disease Activity Index (CDAI) score ranging from 220 to 450 inclusive during the observation period~* C-reactive protein (CRP) of 1 mg/dL or higher in the laboratory test performed at the start of the observation period~Exclusion Criteria:~* Stoma patient~* Patients with a history of severe hypersensitivity or anphylactic reaction to anti-TNF alpha antibody~* Patients who participated in a clinical study with CDP870~* Pregnant or lactating patients, patients of childbearing potential, or patients who will attempt pregnancy during the study period~* Patients who are judged inappropriate for enrollment by the principal investigator or subinvestigators~Exclusion Criteria:

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol 200 mg (Type: EXPERIMENTAL): Subjects received one subcutaneous (sc) injection of 200 mg CZP and one injection of Placebo to maintain the study blind on Weeks 0 (first dose), 2 and 4.
- Certolizumab pegol 400 mg (Type: EXPERIMENTAL): Subjects received two subcutaneous (sc) injections of 200 mg CZP on Weeks 0 (first dose), 2 and 4.
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received two subcutaneous (sc) injections of Placebo on Weeks 0 (first dose), 2 and 4.

Based on this trial design, predict the completion outcome and termination type (if applicable).